Eliem Therapeutics, Inc.

NasdaqGM:ELYM Stock Report

Mkt Cap: US$102.0m

Eliem Therapeutics Future Growth

How is Eliem Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGM:ELYM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-83-142-1203
12/31/2024N/A-69-56-613
12/31/2023N/A-51-46-474
9/30/2022N/A-48-37-37N/A
6/30/2022N/A-49-46-46N/A
3/31/2022N/A-46-40-40N/A
12/31/2021N/A-52-36-36N/A
9/30/2021N/A-57-34-34N/A
6/30/2021N/A-49-23-23N/A
3/31/2021N/A-40-19-19N/A
12/31/2020N/A-23-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELYM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ELYM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ELYM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ELYM's revenue is forecast to grow faster than the US market.

High Growth Revenue: ELYM is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ELYM's Return on Equity is forecast to be high in 3 years time


Discover growth companies